Cellworks AI-Driven Modeling System Can Help Predict Response to AML, MDS Therapies

Originally published on GenomeWeb/360Dx

The Cellworks Group has announced the results of clinical studies that showed how physicians could leverage the firm's computational biology modeling technology for genomic profiling of tumors and predicting patient response to chemotherapies.

In a prospective clinical study, called iCare 1, the Cellworks artificial intelligence-based technology was 90 percent accurate in predicting the response to standard-of-care treatments in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Read more (PDF)

Matthew Matassa